The first session of the CMT Research Foundation’s Gene Therapies Demystified series gave attendees the building blocks: what gene therapy is, why CMT is a compelling target, and what the science suggests about its potential. The second session moved from the foundational to the practical, tackling clinical trial design.

The final installment, Policy, Access, and the Road Ahead, examines the federal landscape surrounding gene therapy development. As regulatory agencies, Congress, and the administration navigate a period of significant change, the decisions being made right now will have lasting consequences for patients with CMT and rare disease communities broadly.

Date: July 16, 2026
Time: 7:00 p.m. ET
Location: Zoom

June 18, 2026

May 7, 2026